Brochure: Neuroscience solutions
Complete solutions for neurological disease research and discovery - helping you to better understand diseases to improve patient outcomes.
List view / Grid view
Complete solutions for neurological disease research and discovery - helping you to better understand diseases to improve patient outcomes.
In pre-clinical studies, senolytic drugs were found to reduce inflammation and death from COVID-19 in older mice.
Drug molecules from pine and spruce trees can affect certain ion channels and had antiseizure effects in pre-clinical studies.
Scientists have found four clinically approved drugs and nine compounds with the potential to be repurposed as therapeutics for COVID-19.
The experimental drug TEMPOL has demonstrated antiviral activity against COVID-19 in a pre-clinical study in cell cultures.
We discuss how liquid handling automation supports drug discovery workflows & highlight opportunities to improve the efficiency and quality of these.
A new high-throughput screening platform has been used to identify two compounds with antiviral activity against the Nipah and Hendra viruses.
Tabernanthalog (TBG), similar to the psychedelic drug ibogaine, corrected stress-induced behavioural deficits in mice.
Scientists have developed six new derivatives of 4-chloro-1,2-dithiol-3-thione, which have all demonstrated anticancer effects in pre-clinical studies.
A synthetic antiviral named R327 has shown promise in initial tests against SARS-CoV-2 and is now advancing to the next stage of in vitro studies.
A new assay has been developed to screen for small molecule inhibitors of the Rh5 protein, which is essential for malaria parasite survival.
Dr Sotirios Karathanasis discusses the history of cannabis as a treatment and delves into the process of turning plant-based medicines into clinically proven drugs.
Scientists have created an antiviral therapy using lipid nanoparticles that deliver siRNA to the lungs to treat COVID-19 in mice.
Having identified the histone demethylase KDM5A as a multiple myeloma target, researchers developed a KDM5 inhibitor to treat the cancer.
Researchers have developed a set of compounds designed to stop the malaria parasite being able to burst out of red blood cells and replicate.